Skip to main content
Erschienen in: Pediatric Cardiology 1/2013

01.01.2013 | Original Article

Comparison of the Efficacy of Different-Sized Amplatzer Duct Occluders (I, II, and II AS) in Children Weighing Less Than 10 kg

verfasst von: Osman Baspinar, Ahmet Irdem, Ercan Sivasli, Derya Aydin Sahin, Metin Kilinc

Erschienen in: Pediatric Cardiology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The transcatheter closure of patent ductus arteriosus (PDA) may cause more complications in small children. Amplatzer (St. Jude Medical, Plymouth, MN) has produces three types of devices for ductal occlusion: the Amplatzer duct occluder I (ADO I) and II (ADO II) and the recently introduced ADO II additional sizes (ADO II AS). We performed this study to determine the efficacy and complication rates in children who weigh <10 kg for the three types of devices used in our clinic. Between February 2007 and March 2012, 77 patients weighing <10 kg had their PDAs occluded with ADOs. The mean age of the patients was 0.76 ± 0.44 years (range 17 days–2 years), and their mean weight was 6.73 ± 2.05 (range 1.2–9.9) kg. In total, 54 girls (70.1 %) and 23 boys (29.9 %) with a mean pulmonary ductus diameter of 2.55 ± 1.0 (1.08–5.94) mm were included in the study. The ADO I was used in 26 patients (33.8 %); the ADO II was used in 43 patients (55.8 %); and the ADO II AS was used in 8 patients (10.4 %). The mean ages of patients with the ADO I, ADO II, and ADO II AS were 1.07 ± 0.48, 0.66 ± 0.31, and 0.28 ± 0.17 years (p < 0.05), respectively. Their mean weights were 7.86 ± 1.45, 6.50 ± 1.85, and 4.36 ± 2.49 kg (p < 0.05), respectively. Their mean narrowest ductal diameters were 3.11 ± 0.96, 2.25 ± 1.06, and 2.33 ± 1.01 mm (p < 0.05), respectively. The use of the ADO II and ADO II AS was found to be more common in type C defects. One patient with the ADO I and 5 patients with the ADO II (7.8 %) developed varying degrees of left pulmonary artery stenosis or iatrogenic aortic coarctation. In 1 patient, the ADO II AS was replaced with the ADO II due to a significant residual shunt observed during the procedure. Each of the ADOs has its own advantages and disadvantages. Although the ADO I is convenient for medium- and large-sized defects, the ADO II and ADO II AS can be used both anterogradely and retrogradely. The ADO II AS is safe and efficient to use in small infants.
Literatur
1.
Zurück zum Zitat Bass JL, Wilson N (2011) Transcatheter occlusion of the patent ductus arteriorus in infants—experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv. doi:10.1002/ccd.22931 Bass JL, Wilson N (2011) Transcatheter occlusion of the patent ductus arteriorus in infants—experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv. doi:10.​1002/​ccd.​22931
2.
Zurück zum Zitat Bentham J, Meur S, Hudsmith L, Archer N, Wilson N (2011) Echocardiographically guided catheter closure of arterial ducts in small preterm infants on the neonatal intensive care unit. Catheter Cardiovasc Interv 77:409–415PubMedCrossRef Bentham J, Meur S, Hudsmith L, Archer N, Wilson N (2011) Echocardiographically guided catheter closure of arterial ducts in small preterm infants on the neonatal intensive care unit. Catheter Cardiovasc Interv 77:409–415PubMedCrossRef
3.
Zurück zum Zitat Bhole V, Miller P, Mehta C, Stumper O, Reinhardt Z, De Giovanni JV (2009) Clinical evaluation of the new Amplatzer duct occluder II for patent arterial duct occlusion. Catheter Cardiovasc Interv 74:762–769PubMedCrossRef Bhole V, Miller P, Mehta C, Stumper O, Reinhardt Z, De Giovanni JV (2009) Clinical evaluation of the new Amplatzer duct occluder II for patent arterial duct occlusion. Catheter Cardiovasc Interv 74:762–769PubMedCrossRef
4.
Zurück zum Zitat Brunetti MA, Ringel R, Owada C, Coulson J, Jennings JM, Hoyer MH et al (2010) Percutaneous closure of patent ductus arteriosus: a multi-institutional registry comparing multiple devices. Catheter Cardiovasc Interv 76:696–702PubMedCrossRef Brunetti MA, Ringel R, Owada C, Coulson J, Jennings JM, Hoyer MH et al (2010) Percutaneous closure of patent ductus arteriosus: a multi-institutional registry comparing multiple devices. Catheter Cardiovasc Interv 76:696–702PubMedCrossRef
5.
Zurück zum Zitat Butera G, De Rosa G, Chessa M, Piazza L, Delogu A, Frigiola A et al (2004) Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart 90:1467–1470PubMedCrossRef Butera G, De Rosa G, Chessa M, Piazza L, Delogu A, Frigiola A et al (2004) Transcatheter closure of persistent ductus arteriosus with the Amplatzer duct occluder in very young symptomatic children. Heart 90:1467–1470PubMedCrossRef
6.
Zurück zum Zitat Celiker A, Aypar E, Karagoz T, Dilber E, Ceviz N (2005) Transcatheter closure of patent ductus arteriosus with Nit-Occlud coils. Catheter Cardiovasc Interv 65:569–576PubMedCrossRef Celiker A, Aypar E, Karagoz T, Dilber E, Ceviz N (2005) Transcatheter closure of patent ductus arteriosus with Nit-Occlud coils. Catheter Cardiovasc Interv 65:569–576PubMedCrossRef
7.
Zurück zum Zitat Dimas VV, Takao C, Ing FF, Mattamal R, Nugent AW, Grifka RG et al (2010) Outcomes of transcatheter occlusion of patent ductus arteriosus in infants weighing ≤6 kg. JACC Cardiovasc Interv 3:1295–1299PubMedCrossRef Dimas VV, Takao C, Ing FF, Mattamal R, Nugent AW, Grifka RG et al (2010) Outcomes of transcatheter occlusion of patent ductus arteriosus in infants weighing ≤6 kg. JACC Cardiovasc Interv 3:1295–1299PubMedCrossRef
8.
Zurück zum Zitat Dua J, Chessa M, Piazza L, Negura D, Micheletti A, Bussadori C et al (2009) Initial experience with the new Amplatzer duct occluder II. J Invasive Cardiol 21:401–405PubMed Dua J, Chessa M, Piazza L, Negura D, Micheletti A, Bussadori C et al (2009) Initial experience with the new Amplatzer duct occluder II. J Invasive Cardiol 21:401–405PubMed
9.
Zurück zum Zitat Faella HJ, Hijazi ZM (2000) Closure of the patent ductus arteriosus with the Amplatzer PDA device: immediate results of the international clinical trial. Catheter Cardiovasc Interv 51:50–54PubMedCrossRef Faella HJ, Hijazi ZM (2000) Closure of the patent ductus arteriosus with the Amplatzer PDA device: immediate results of the international clinical trial. Catheter Cardiovasc Interv 51:50–54PubMedCrossRef
10.
Zurück zum Zitat Forsey J, Kenny D, Morgan G, Hayes A, Turner M, Tometzki A et al (2009) Early clinical experience with the new Amplatzer duct occluder II for closure of the persistent arterial duct. Catheter Cardiovasc Interv 74:615–623PubMedCrossRef Forsey J, Kenny D, Morgan G, Hayes A, Turner M, Tometzki A et al (2009) Early clinical experience with the new Amplatzer duct occluder II for closure of the persistent arterial duct. Catheter Cardiovasc Interv 74:615–623PubMedCrossRef
11.
Zurück zum Zitat Francis E, Singhi AK, Lakshmivenkateshaiah S, Kumar RK (2010) Transcatheter occlusion of patent ductus arteriosus in pre-term infants. JACC Cardiovasc Interv 3:550–555PubMedCrossRef Francis E, Singhi AK, Lakshmivenkateshaiah S, Kumar RK (2010) Transcatheter occlusion of patent ductus arteriosus in pre-term infants. JACC Cardiovasc Interv 3:550–555PubMedCrossRef
12.
Zurück zum Zitat Ghasemi A, Pandya S, Reddy SV, Turner DR, Du W, Navabi M et al (2010) Trans-catheter closure of patent ductus arteriosus—what is the best device? Catheter Cardiovasc Interv 76:687–695PubMedCrossRef Ghasemi A, Pandya S, Reddy SV, Turner DR, Du W, Navabi M et al (2010) Trans-catheter closure of patent ductus arteriosus—what is the best device? Catheter Cardiovasc Interv 76:687–695PubMedCrossRef
13.
Zurück zum Zitat Krichenko A, Benson LN, Burrows P, Moes CA, McLaughlin P, Freedom RM (1989) Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol 63:877–880PubMedCrossRef Krichenko A, Benson LN, Burrows P, Moes CA, McLaughlin P, Freedom RM (1989) Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol 63:877–880PubMedCrossRef
14.
Zurück zum Zitat Lin CC, Hsieh KS, Huang TC, Weng KP (2009) Closure of large patent ductus arteriosus in infants. Am J Cardiol 103:857–861PubMedCrossRef Lin CC, Hsieh KS, Huang TC, Weng KP (2009) Closure of large patent ductus arteriosus in infants. Am J Cardiol 103:857–861PubMedCrossRef
15.
Zurück zum Zitat Masura J, Tittel P, Gavora P, Podnar T (2006) Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. Am Heart J 151:755.e7–755.e10CrossRef Masura J, Tittel P, Gavora P, Podnar T (2006) Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. Am Heart J 151:755.e7–755.e10CrossRef
16.
Zurück zum Zitat Pass RH (2006) Amplatzer duct occluder device: a new technology for the closure of the moderate-to-large-sized patent ductus arteriosus. Expert Rev Med Devices 3:291–296PubMedCrossRef Pass RH (2006) Amplatzer duct occluder device: a new technology for the closure of the moderate-to-large-sized patent ductus arteriosus. Expert Rev Med Devices 3:291–296PubMedCrossRef
17.
Zurück zum Zitat Pass RH, Hijazi Z, Hsu DT, Lewis V, Hellenbrand WE (2004) Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll Cardiol 44:513–519PubMedCrossRef Pass RH, Hijazi Z, Hsu DT, Lewis V, Hellenbrand WE (2004) Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll Cardiol 44:513–519PubMedCrossRef
18.
Zurück zum Zitat Rao PS, Sideris EB, Haddad J, Rey C, Hausdorf G, Wilson AD et al (1993) Transcatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial clinical experience. Circulation 88:1119–1126PubMedCrossRef Rao PS, Sideris EB, Haddad J, Rey C, Hausdorf G, Wilson AD et al (1993) Transcatheter occlusion of patent ductus arteriosus with adjustable buttoned device. Initial clinical experience. Circulation 88:1119–1126PubMedCrossRef
19.
Zurück zum Zitat Thanopoulos B, Eleftherakis N, Tzannos K, Stefanadis C (2008) Transcatheter closure of the patent ductus arteriosus using the new Amplatzer duct occluder: initial clinical applications in children. Am Heart J 156:917.e1–917.e6CrossRef Thanopoulos B, Eleftherakis N, Tzannos K, Stefanadis C (2008) Transcatheter closure of the patent ductus arteriosus using the new Amplatzer duct occluder: initial clinical applications in children. Am Heart J 156:917.e1–917.e6CrossRef
20.
Zurück zum Zitat Tomita H, Uemura S, Haneda N, Soga T, Matsuoka T, Nishioka T et al (2009) Coil occlusion of PDA in patients younger than 1 year: risk factors for adverse events. J Cardiol 53:208–213PubMedCrossRef Tomita H, Uemura S, Haneda N, Soga T, Matsuoka T, Nishioka T et al (2009) Coil occlusion of PDA in patients younger than 1 year: risk factors for adverse events. J Cardiol 53:208–213PubMedCrossRef
Metadaten
Titel
Comparison of the Efficacy of Different-Sized Amplatzer Duct Occluders (I, II, and II AS) in Children Weighing Less Than 10 kg
verfasst von
Osman Baspinar
Ahmet Irdem
Ercan Sivasli
Derya Aydin Sahin
Metin Kilinc
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Pediatric Cardiology / Ausgabe 1/2013
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-012-0393-6

Weitere Artikel der Ausgabe 1/2013

Pediatric Cardiology 1/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.